New #JITC article: The cold immunological landscape of ATM-deficient cancers bit.ly/4k2rNfY ipstone Lorenzo Galluzzi Nadeem Riaz

📢Safety and potential efficacy of PARP inhibitor with #radiotherapy in homologous recombination defective triple negative #breastcancer‼️ Maybe radiation/drug combos are slowly but surely coming? IJROBP - The Red Journal Nadeem Riaz Prof. Mechthild Krause #radbio #bcsm redjournal.org/article/S0360-…

Remarkable efforts to obtain on-treatment tissue to study TME. CRT with sequential pembro *might* be more favorable than concurrent pembro. ascopubs.org/doi/pdf/10.120… Sana Karam, MD, PhD Nadeem Riaz David Sher Aadel Chaudhuri, MD PhD Scott Bratman

Interesting data on some exceptional respones to Lu-PSMA in ATM-mutated cancers. In line with EBRT data.

🔔Exciting results of adj cancer directed vaccines for high risk respected HPVneg HNSCC. #ASCO25 Congrats to the investigators for this novel work.

👋🚨NIVOPOSTOP GORTEC #ASCO25 ‼️adj nivo x1 ➡️concurrent nivo-CRT➡️ nivo improved DFS (mostly LRC). Waiting for OS results.

Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning

AI-based tumor board! This space is evolving so fast.... this is a great paper on whats about to come very soon, and very widely....

What changed in E3311 long-term data? ✔️Transoral surgery + 50 Gy = durable control in intermediate-risk HPV+ OPC ✔️No OS or PFS difference by smoking or subsite ⚠️Observation alone in N1? Late recurrences → risky 🔑Pathologic risk-based adjuvant therapy works

🚨🚨🚨 pembro in localized hnscc is finally approved !

👀Using an autonomous agent based on o3-mini and GPT-4.1, a team from Harvard, MIT & other institutions reproduced and updated an entire issue of Cochrane Reviews in two days… saving 12 person-years of work! The AI reviews captured more papers & were more accurate than humans.

Led by Drs. Zakeri & Nancy Lee, we report early Memorial Sloan Kettering Radiation Oncology exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 shorturl.at/CKA6W

In Journal of Clinical Oncology, our reflections on the timely ASCO TORS guideline Nancy Lee Nadeem Riaz 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status

nejm.org/doi/full/10.10…

Oof. Polygenic scores for IQ lose 75% of their explained variance when adding family controls, even worse than the attenuation for Educational Attainment. These are the scores Silicon Valley is using to select embryos 😬. A few thoughts on this study ...

How well does AI based assessment of mutations in DNA repair genes in cancer work -- we took a look 👇 great work by Shu Yazaki, MD, PhD and team.

This R packages can transform any plot using color pallets from painting at the Museum of Modern Art in New York github.com/BlakeRMills/Me…

It makes no sense that safety data (e.g. adverse events) for failed drugs are not made publicly available. This would be a huge resource for retrospective analysis.

💡 Cancer cells don’t just mutate—they reorganize their DNA in 3D space. Our new study shows how the genome’s folding pattern shifts as tumors progress, cell by cell 🧩🧬. It’s the first 3D genome atlas of cancer progression. Thread 👇

Great to see this out finally🔥 Successful integration of a targeted agent (olaparib) with #radiotherapy in extensive stage SCLC👍 These trials difficult to do‼️ (we failed to commence PARPi + chemoRT trial☹️) Benjamin Lok, MD Salma Jabbour MGH Thoracic Oncology aacrjournals.org/clincancerres/…